We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Here you can learn more about our toolbox of reporter bioassays and cell health assays used to characterize and develop novel mAb-based therapeutics. In addition, you will find product listings and resources that provide examples of how researchers use our bioassays throughout the drug development workflow. 

Bioassays are available to interrogate the following biological functions:

  • Fc effector activity     
  • Immune checkpoint modulation     
  • T cell retargeting
  • Cytokine and growth factor signaling     
  • Tumor antigen-specific cell killing

A Multipronged Approach to Antibody Therapeutics

Antibody-based therapeutic drugs can be broadly classified into six categories depending on their mechanism of action (MOA), as indicated in the schematic below. Many biologic drugs function via a single mechanism; however, newer drug candidates are being designed that function through multiple mechanisms. The use of MOA-based bioassays to measure the activity of drug candidates is critical throughout the drug development workflow.

Multi pronged approach to Ab therapeutics
Adapted from Weiner, et al. (2013) Nature Reviews Cancer 15, 361–70.

Explore our portfolio of MOA-based reporter bioassays and cell health assays by searching for your therapeutic target or biological endpoint: